TY - JOUR
T1 - Chemosensitivity profile assay of circulating cancer cells
T2 - Prognostic and predictive value in epithelial tumors
AU - Gazzaniga, Paola
AU - Naso, Giuseppe
AU - Gradilone, Angela
AU - Cortesi, Enrico
AU - Gandini, Orietta
AU - Gianni, Walter
AU - Fabbri, Maria Agnese
AU - Vincenzi, Bruno
AU - Di Silverio, Franco
AU - Frati, Luigi
AU - Aglianò, Anna Maria
AU - Cristofanilli, Massimo
PY - 2010/5/15
Y1 - 2010/5/15
N2 - The prognostic value associated with the detection of circulating tumor cells (CTCs) in metastatic breast cancer by the CellSearch™ technology raise additional issues regarding the biological value of this information. We postulated that a drug-resistance profile of CTCs may predict response to chemotherapy in cancer patients and therefore could be used for patient selection. One hundred 5 patients with diagnosis of carcinoma were enrolled in a prospective trial. CTCs were isolated from peripheral blood, and positive samples were evaluated for the expression of a panel of genes involved in anticancer drugs resistance. The drug-resistance profile was correlated with disease-free survival (DFS; patients in adjuvant setting) and time to progression (TTP; metastatic patients) in a 24-months follow-up. Objective response correlation was a secondary end point. Fifty-one percent of patients were found positive for CTCs while all blood samples from healthy donors were negative. The drug-resistance profile correlates with DFS and TTP (p <0.001 in both). Sensitivity of the test: able to predict treatment response in 98% of patients. Specificity of the test: 100%; no sample from healthy subject was positive for the presence of CTCs. Positive and negative predictive values were found to be 96.5 and 100%, respectively. We identified a drug-resistance profile of CTCs, which is predictive of response to chemotherapy, independent of tumor type and stage of disease. This approach may represent a first step toward the individualization of chemotherapy in cancer patients.
AB - The prognostic value associated with the detection of circulating tumor cells (CTCs) in metastatic breast cancer by the CellSearch™ technology raise additional issues regarding the biological value of this information. We postulated that a drug-resistance profile of CTCs may predict response to chemotherapy in cancer patients and therefore could be used for patient selection. One hundred 5 patients with diagnosis of carcinoma were enrolled in a prospective trial. CTCs were isolated from peripheral blood, and positive samples were evaluated for the expression of a panel of genes involved in anticancer drugs resistance. The drug-resistance profile was correlated with disease-free survival (DFS; patients in adjuvant setting) and time to progression (TTP; metastatic patients) in a 24-months follow-up. Objective response correlation was a secondary end point. Fifty-one percent of patients were found positive for CTCs while all blood samples from healthy donors were negative. The drug-resistance profile correlates with DFS and TTP (p <0.001 in both). Sensitivity of the test: able to predict treatment response in 98% of patients. Specificity of the test: 100%; no sample from healthy subject was positive for the presence of CTCs. Positive and negative predictive values were found to be 96.5 and 100%, respectively. We identified a drug-resistance profile of CTCs, which is predictive of response to chemotherapy, independent of tumor type and stage of disease. This approach may represent a first step toward the individualization of chemotherapy in cancer patients.
KW - Chemotherapy
KW - Circulating tumor cells
KW - Drug resistance
UR - http://www.scopus.com/inward/record.url?scp=77951233874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951233874&partnerID=8YFLogxK
U2 - 10.1002/ijc.24953
DO - 10.1002/ijc.24953
M3 - Article
C2 - 19821489
AN - SCOPUS:77951233874
VL - 126
SP - 2437
EP - 2447
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 10
ER -